CTX130

· CRISPR Therapeutics AG

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CTX130, covering 2025-01-08 to 2025-01-08. Get the full timeline:

Most recent: Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) [Phase 1]

See pricing